Q4 2024 GSK plc Earnings Call Transcript
Key Points
- GSK PLC (GSK) reported an 8% increase in sales for 2024, reaching over GBP31 billion, driven by strong growth in specialty medicines.
- Core operating profit rose by 13% and core EPS increased by 12%, leading to two upgrades in guidance for 2024.
- The company announced a dividend increase to 61p per share and plans to pay 64p in 2025, reflecting strong financial performance.
- GSK PLC (GSK) expects five new product approvals in 2025, including BLENREP for multiple myeloma and depomokimab for severe asthma.
- The company achieved 13 positive Phase III readouts in 2024, strengthening its R&D pipeline, particularly in oncology and respiratory immunology.
- Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix.
- The introduction of the Inflation Reduction Act is expected to have a GBP150 million to GBP200 million impact on HIV sales in 2025.
- GSK PLC (GSK) adjusted its expectations for vaccine sales growth, anticipating a decrease in low single-digit percent in 2025.
- The company faces pricing and genericization pressures in its General Medicines portfolio, expecting sales to be broadly flat in 2025.
- There is significant speculation and potential changes to U.S. vaccine policy, contributing to short-term pressures on the vaccine market.
Hello, everyone. Welcome to today's call and webcast. The presentation was sent to our distribution list by email, and you can also find it on gsk.com.
Please turn to slide 2. This is the usual Safe Harbor statement. We will comment on our performance using constant exchange rates, or CER, and excluding COVID solutions, unless stated otherwise.
Please turn to slide 3. Today's call will last approximately one hour and 15 minutes, with the presentation taking around 40 minutes and the remaining time for your questions. Our speakers today are Emma Walmsley, Luke Miels, Julie Brown, and David Redfern, who will be covering HIV in the absence of Deborah Waterhouse, who's recovering from a successful medical procedure. And Tony Wood will be joining us for Q&A. Please ask only one to two questions so that everyone has a chance to participate.
Turning to slide 4, I will now hand the call to Emma.
Thank you, Jeff, and welcome to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
